News summaryThe Motley FoolNov 7, 2026, 09:15 PM
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
PFEpharmaceuticals
After dropping its internally developed GLP-1 drug, Pfizer acquired a company with a GLP-1 drug still in development. [[fact-sen0vfvw6]] Pfizer currently has multiple clinical trials underway in the weight-loss space. [[fact-phb8bs6rr]] Recent trials showed its GLP-1 drug reduced weight by 12%, including after the shift to monthly shots. [[fact-jazuvyvxk]] Pfizer has 10 late-stage trials in its weight-loss portfolio. [[fact-9lbrguebv]]